Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes
Authors
Keywords
-
Journal
Diabetes & Vascular Disease Research
Volume -, Issue -, Pages 147916411882537
Publisher
SAGE Publications
Online
2019-02-02
DOI
10.1177/1479164118825376
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Heart Failure After Ischemic Stroke or TIA in Insulin-Resistant Patients Without Diabetes Treated with Pioglitazone
- (2018) Lawrence H. Young et al. CIRCULATION
- Impact of treatment with pioglitazone on stroke outcomes: A real-world database analysis
- (2018) Christopher Ll Morgan et al. DIABETES OBESITY & METABOLISM
- Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes
- (2017) Aidin Rawshani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis
- (2017) Hung-Wei Liao et al. BMJ Open
- Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial
- (2017) Olga Vaccaro et al. Lancet Diabetes & Endocrinology
- Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke
- (2017) Shadi Yaghi et al. CIRCULATION
- Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
- (2016) Kenneth Cusi et al. ANNALS OF INTERNAL MEDICINE
- Clinical Update: Cardiovascular Disease in Diabetes Mellitus
- (2016) Cecilia C. Low Wang et al. CIRCULATION
- Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes
- (2016) E. Erdmann et al. DIABETES OBESITY & METABOLISM
- Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor
- (2016) R. A. DeFronzo et al. DIABETES OBESITY & METABOLISM
- Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD
- (2016) Fernando Bril et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
- (2016) Walter N. Kernan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
- (2015) M. A. Abdul-Ghani et al. DIABETES OBESITY & METABOLISM
- Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes
- (2015) James D. Lewis et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Type 2 diabetes mellitus
- (2015) Ralph A. DeFronzo et al. Nature Reviews Disease Primers
- A comparison of all-cause mortality with pioglitazone and insulin in type 2 diabetes: an expanded analysis from a retrospective cohort study
- (2014) Jiao Yang et al. CURRENT MEDICAL RESEARCH AND OPINION
- Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis
- (2014) Daniel Levin et al. DIABETOLOGIA
- What are the pharmacotherapy options for treating prediabetes?
- (2014) Giuseppe Daniele et al. EXPERT OPINION ON PHARMACOTHERAPY
- The Disposition Index Does Not Reflect β-Cell Function in IGT Subjects Treated With Pioglitazone
- (2014) Ralph A. DeFronzo et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Prevention of Diabetes With Pioglitazone in ACT NOW: Physiologic Correlates
- (2013) R. A. DeFronzo et al. DIABETES
- Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013
- (2013) G. Schernthaner et al. DIABETES CARE
- In Vivo Actions of Peroxisome Proliferator-Activated Receptors: Glycemic control, insulin sensitivity, and insulin secretion
- (2013) R. Eldor et al. DIABETES CARE
- Observational follow-up of the PROactive study: a 6-year update
- (2013) E. Erdmann et al. DIABETES OBESITY & METABOLISM
- The global NAFLD epidemic
- (2013) Rohit Loomba et al. Nature Reviews Gastroenterology & Hepatology
- Pioglitazone Slows Progression of Atherosclerosis in Prediabetes Independent of Changes in Cardiovascular Risk Factors
- (2012) Aramesh Saremi et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Prevalence of Prediabetes and Diabetes and Metabolic Profile of Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
- (2012) C. Ortiz-Lopez et al. DIABETES CARE
- Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy
- (2012) J. Rosenstock et al. DIABETES CARE
- What Next after Metformin? A Retrospective Evaluation of the Outcome of Second-Line, Glucose-Lowering Therapies in People with Type 2 Diabetes
- (2012) Christopher Ll. Morgan et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of Clopidogrel Added to Aspirin in Patients with Recent Lacunar Stroke
- (2012) NEW ENGLAND JOURNAL OF MEDICINE
- Insulin Resistance and Risk of Incident Cardiovascular Events in Adults without Diabetes: Meta-Analysis
- (2012) Karin B. Gast et al. PLoS One
- Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone: Interim report of a longitudinal cohort study
- (2011) J. D. Lewis et al. DIABETES CARE
- Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: An analysis of the PROactive study population
- (2011) Wolfram Doehner et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Preservation of β-Cell Function: The Key to Diabetes Prevention
- (2011) Ralph A. DeFronzo et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
- (2011) Ralph A. DeFronzo et al. NEW ENGLAND JOURNAL OF MEDICINE
- PPARs: diverse regulators in energy metabolism and metabolic diseases
- (2010) Yong-Xu Wang CELL RESEARCH
- Thiazolidinediones and fracture risk in patients with Type 2 diabetes
- (2010) D. J. Betteridge DIABETIC MEDICINE
- Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009
- (2010) R. A. DeFronzo DIABETOLOGIA
- The Natural History of Non-Alcoholic Fatty Liver Disease
- (2010) Stephen Caldwell et al. DIGESTIVE DISEASES
- Effects of Pioglitazone on Intramyocellular Fat Metabolism in Patients with Type 2 Diabetes Mellitus
- (2010) Mandeep Bajaj et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pioglitazone Improves Cardiac Function and Alters Myocardial Substrate Metabolism Without Affecting Cardiac Triglyceride Accumulation and High-Energy Phosphate Metabolism in Patients With Well-Controlled Type 2 Diabetes Mellitus
- (2009) Rutger W. van der Meer et al. CIRCULATION
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
- (2009) R. A. DeFronzo DIABETES
- Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial
- (2009) D. K. Coletta et al. DIABETOLOGIA
- Risk of Fractures with Glitazones
- (2009) Michael Bodmer et al. DRUG SAFETY
- Effect of pioglitazone on left ventricular diastolic function and fibrosis of type III collagen in type 2 diabetic patients
- (2009) Gen Terui et al. Journal of Cardiology
- Impact of peripheral arterial disease in patients with diabetes—Results from PROactive (PROactive 11)
- (2008) J.A. Dormandy et al. ATHEROSCLEROSIS
- Expression of Peroxisome Proliferator-Activated Receptor-γ in Key Neuronal Subsets Regulating Glucose Metabolism and Energy Homeostasis
- (2008) David A. Sarruf et al. ENDOCRINOLOGY
- Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial
- (2008) Vlad Ratziu et al. GASTROENTEROLOGY
- Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes
- (2008) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The Peroxisome Proliferator-Activated Receptor-γ Agonist Pioglitazone Represses Inflammation in a Peroxisome Proliferator-Activated Receptor-α–Dependent Manner In Vitro and In Vivo in Mice
- (2008) Gabriela Orasanu et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
- (2008) William Duckworth et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started